Apalutamide Tablets

Apalutamide tablets are androgen receptor inhibitors. The main indications are:
Adult patients with metastatic endocrine-sensitive prostate cancer (mHSPC);
Adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis.
The main ingredient of apalutamide tablets is apalutamide, which inhibits the binding of androgen receptors to DNA, thereby inhibiting the transcription of target genes. Apalutamide can also affect other signaling pathways, including PI3K, MAPK and PI3K/Akt, further inhibiting the growth and spread of prostate cancer cells.